Home
Reinventing Remote
Robotic Surgery
Advanced Magnetic Technology

We believe everyone
should have access to
life-saving interventions

Developing next-generation telerobotic solutions for critical of endovascular interventions that will redefine patient care and deliver superior outcomes.
Critical Endovascular Interventions
Stroke is the second most common cause of death and the number one cause of long-term disability.

In an acute ischemic stroke where a thrombectomy is needed, timely intervention is key.

Receiving a thrombectomy quickly after a stroke onset minimizes brain damage and improves the prospects of recovery and rehabilitation.

Yet, millions of people don’t have timely access to this critical treatment due to geographical restrictions.

This is where we come in.
About Us
Our Telerobotics Intervention System
By using magnetism and ultra-flexible robotic devices, we can treat a variety of critical endovascular diseases, starting with stroke.

Our cutting-edge telerobotics system enables physicians to perform thrombectomies no matter where the patient is located. This reduces transfer and waiting times, allowing for faster treatment.
Our Technology
Partner
With Us
Partner
With Us
Our technology unveils new
possibilities for telerobotic
endovascular interventions.
Get in touch to learn more.
Telerobotics Intervention System
Revolutionary magnetic navigation system. Ultra-flexible microrobotic devices. AI-compatible software. Borderless, transformative treatments.
Latest News
Our Team
Matt Curran
CEO and Co-Founder
Matt Curran
CEO and Co-Founder
  • 20+ years commercial experience at Medtronic
  • MBA, Edinburgh Business School
Dr. Christophe Chautems
CTO and Co-Founder
Dr. Christophe Chautems
CTO and Co-Founder
  • Remote navigation experience at NASA
  • 10+ years research on magnetic navigation
  • PhD, ETH Zurich
Prof. Dr. Bradley Nelson
Mentor and Co-Founder
Prof. Dr. Bradley Nelson
Mentor and Co-Founder
Dr. Grace Katzschmann
COO
Dr. Grace Katzschmann
COO
  • 10 years start up experience (social impact, biotech, venture capital)
  • PhD, Harvard-MIT
Our Partners